Strategic Advisors’s AstraZeneca AZN Stock Holding History

Strategic Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$327K	Sell	1,724 -15	-0.9%	-$2.82K	0.07%	142
2026 Q1	$343K	Sell	1,739 -2	-0.1%	-$386	0.06%	155
2025 Q4	$320K	Hold	1,741	–	–	0.05%	155
2025 Q3	$267K	Buy	1,741 +1	+0.1%	+$151	0.04%	165
2025 Q2	$243K	Hold	1,740	–	–	0.05%	153
2025 Q1	$256K	Sell	1,740 -74	-4%	-$10.7K	0.05%	166
2024 Q4	$238K	Buy	1,814 +52	+3%	+$7.28K	0.04%	179
2024 Q3	$275K	Hold	1,762	–	–	0.05%	181
2024 Q2	$275K	Sell	1,762 -525	-23%	-$79K	0.05%	178
2024 Q1	$310K	Buy	2,287 +29	+1%	+$3.84K	0.06%	171
2023 Q4	$304K	Buy	2,258 +8	+0.4%	+$1.04K	0.06%	169
2023 Q3	$305K	Hold	2,250	–	–	0.06%	164
2023 Q2	$322K	Hold	2,250	–	–	0.06%	154
2023 Q1	$312K	Hold	2,250	–	–	0.06%	161
2022 Q4	$305K	Hold	2,250	–	–	0.07%	154
2022 Q3	$246K	Hold	2,250	–	–	0.05%	164
2022 Q2	$297K	Hold	2,250	–	–	0.06%	153
2022 Q1	$298K	Buy	+2,250	New	+$270K	0.05%	161

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Strategic Advisors's AZN Position: Q2 2026 in Review

Strategic Advisors reduced its AstraZeneca (AZN) stake by 0.86% in Q2 2026, selling an estimated $2.82K and leaving 1,724 shares worth $327K. The position accounts for 0.07% of the portfolio, ranked #142.

Strategic Advisors first reported a position in AZN in Q1 2022 and has held it in 18 quarters since. The position peaked at $343K in Q1 2026. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Strategic Advisors held 1,724 shares of AstraZeneca worth $327K as of Q2 2026.
Strategic Advisors sold 15 AstraZeneca shares in Q2 2026, an estimated $2.82K.
AstraZeneca made up 0.07% of Strategic Advisors's portfolio in Q2 2026, its #142 holding.
Strategic Advisors first reported a position in AstraZeneca in Q1 2022 and has held it in 18 quarters since.
Strategic Advisors's AstraZeneca position peaked at $343K in Q1 2026.
1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Strategic Advisors's 13F filing for Q2 2026, filed 28 Jul 2026.